Argus: Anthrax Vaccine Maker Emergent BioSolutions Poised For Earnings Growth
Emergent Biosolutions Inc (NYSE: EBS), a maker of vaccines and products for infectious diseases as well as chemical, biological or nuclear attacks, picked up a sell-side bull Wednesday. Latest Ratings for EBS Da.....»»
Emergent BioSolutions ‘hopeful’ to return to vaccine production, plans to submit response to FDA ‘within days’
On a first-quarter earnings call Thursday, Emergent's CEO addressed a turbulent month for the Gaithersburg biopharmaceutical company......»»
CEO of COVID-19 vaccine maker sold $10M in stock before company destroyed Johnson & Johnson doses
The CEO of Emergent BioSolutions, the government contractor that destroyed 15 million doses of Johnson & Johnson's COVID-19 vaccine, sold more than $10 million worth of his stock in the company before its share prices plummeted......»»
Emergent BioSolutions to enter 5 new countries with anthrax vaccine
The Gaithersburg-based biotech just received approval to introduce its anthrax vaccine in five European countries, a move that brings the possibility of a new and important revenue stream......»»
Emergent BioSolutions receives Health Canada approval for anthrax vaccine NDS
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck"s Pneumococcal Shots - Analyst Says
The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reac.....»»
100 million doses of Johnson & Johnson"s vaccine need to be checked for contamination and may need to be thrown out
The millions of Johnson & Johnson COVID-19 vaccine doses haven't been distributed to the public and are from a plagued Emergent BioSolutions facility. Employees wor.....»»
The Wall Street Journal: Emergent CEO says company made over 100 million doses of J&J vaccine, apologizes for contaminated batch
Emergent BioSolutions Inc. has made enough of a key ingredient to yield more than 100 million doses of Johnson & Johnson’s Covid-19 vaccine, and federal health regulators are evaluating whether to release the shots, Emergent’s chief executive said......»»
Emergent shares slide 2.8% as execs blame J&J vaccine snafu on challenge of making two vaccines to scale
Emergent BioSolutions Inc. executives said part of the blame for a snafu in manufacturing the COVI.....»»
Johnson & Johnson documented contamination risks at Baltimore plant months before vaccine was ruined
The House Oversight select subcommittee on the coronavirus crisis is investigating events at Emergent BioSolutions that led to a vaccine production shutdown that is now in its fifth week......»»
Baltimore biodefense executives face grilling in Congress over botched production of J&J vaccine
The House Select Subcommittee on the Coronavirus Crisis is investigating events at Emergent BioSolutions that led to a vaccine production shutdown that is now in its fifth week......»»
Johnson & Johnson vaccine shipments to states dwindle to zero as production freeze continues
Allocations to states of Johnson & Johnson's one-shot vaccine dry up after contamination crisis at Baltimore subcontractor Emergent BioSolutions.....»»
Emergent BioSolutions downgraded to Hold from Buy at Argus
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Emergent BioSolutions downgraded to Hold from Buy at Argus
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Earnings Watch: With earnings on track for best growth in more than a decade, here come Uber, Lyft and the vaccine makers
After Big Tech reported record pandemic profits last week, corporate earnings are on track for their best performance in more than a decade, but now a new generation of tech companies with their own regulatory issues will take the stage......»»
Emergent BioSolutions Has Supply Of 60M Johnson & Johnson COVID-19 Vaccine Doses Awaiting Approval: Bloomberg
read more.....»»
Emergent BioSolutions Hopeful To Restart Vaccine Production, Plans To Submit Response To FDA Within Days
read more.....»»
FDA inspection of Emergent"s COVID-19 vaccine plant identifies "potential quality issues"
Shares of Emergent BioSolutions Inc. were up 1.3% in trading on Wednesday after the Food and Drug Administration said it inspected a plant in Baltimore that had been scheduled to begin producing Johnson & Johnson's COVID-19.....»»
Could Hewlett Packard Enterprise Stock Rebound, Despite Undue Pessimism?
Despite Hewlett Packard Enterprise Co’s (NYSE: HPE) stock valuation reflecting pessimism around its business prospects, the company appears poised for revenue, free cash flow, and earnings growth, according to Jefferies. Latest R.....»»
Emergent BioSolutions says on track with COVID vaccines, reaffirms guidance after J&J vaccine snafu
Emergent BioS.....»»
Emergent BioSolutions tumbles 14% after J&J says it spoiled 15 million COVID-19 vaccine doses
Shares of Emergent tumbled after an error at its production facility ruined roughly 15 million doses of Johnson & Johnson's coronavirus vaccine. .....»»